Sign in
Taking people in United StatesPhase 1/2

ALXN2350 gene therapy for dilated cardiomyopathy linked to BAG3 gene changes

Tests ALXN2350 gene therapy in adults with BAG3-related dilated cardiomyopathy.

Key facts

Who runs it
Alexion Pharmaceuticals, Inc.
Where
Birmingham, Boston, Cincinnati, Houston, Palo Alto, Philadelphia, and Portland, United StatesSee the 7 sitesAlso in 4 other countries, 5 sites
Registry title
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
Status
Recruiting
Phase
Phase 1/2
People taking part
6 people, planned
Started
24 Oct 2025
Expected to end
27 Jan 2032
Type of study
Interventional
Treatments tested
  • ALXN2350
Record updated
28 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with dilated cardiomyopathy (an enlarged, weakened heart muscle) linked to a change in the BAG3 gene. They get one IV infusion of the gene therapy ALXN2350.

Age
18 Years to 70 Years
Sex
All sexes can join.
Disease stage
Diagnosed dilated cardiomyopathy (DCM) and chronic heart failure for at least 3 months. NYHA Class I, II or III. LVEF (how well the heart pumps) > 15% and ≤ 45% on echocardiography at Screening. The heart must be clearly visible on an ultrasound (echocardiography).
Earlier treatment
People must be on a stable mix of standard heart failure medicines.
Biomarker or test result
A pathogenic or likely pathogenic mutation in BAG3 (a disease-causing gene change).

Main reasons for not taking part

  • Antibodies to AAV9 in the blood
  • A disease-causing gene change in another gene known to cause DCM
  • Worsening heart failure that is not under control (decompensated), or NYHA Class IV
  • Heart rhythm problems in the lower heart chambers that need treatment
  • Serious heart valve disease, or substance abuse that could harm the heart

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Pathogenic or likely pathogenic mutation in BAG3
  • Medical history of diagnosis of DCM
  • Stable combination of HF SoC medications
  • Adequate acoustic windows for echocardiography
  • LVEF > 15% and ≤ 45% at Screening by echocardiography
  • Diagnosis of chronic HF for at least 3 months
  • NYHA Class I/II/III at Screening

Who cannot take part

  • Presence of antibodies to AAV9
  • Cardiac ventricular arrhythmia that requires treatment
  • History of untreated clinically significant valve disease or a Screening confirmation of severe aortic stenosis, severe mitral stenosis, moderate or severe aortic insufficiency or severe mitral insufficiency
  • History of substance abuse that could contribute to cardiac dysfunction; Note: Other inclusion and exclusion criteria may apply
  • Presence of a pathogenic or likely pathogenic variant in another gene where that other gene is authoritatively recognized as causal for DCM
  • Decompensated HF
  • NYHA Class IV

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in United States

Also in 4 other countries, 5 sites

  • Birmingham, AlabamaHospital not named in the registryContact: Nehal VekariyaTaking people
  • Boston, MassachusettsHospital not named in the registryContact: Alyx VogleTaking people
  • Cincinnati, OhioHospital not named in the registryContact: Sara BlackTaking people
  • Houston, TexasHospital not named in the registryContact: Jennifer GarrettTaking people
  • Palo Alto, CaliforniaHospital not named in the registryContact: Shannon SchultzTaking people
  • Philadelphia, PennsylvaniaHospital not named in the registryContact: Joseph PuhlTaking people
  • Portland, OregonHospital not named in the registryContact: Hailey VolkTaking people

About the trial

What the trial wants to find out

This Phase 1/2 study is an open-label, dose finding and dose expansion study investigating the safety, tolerability, and efficacy of a single IV infusion of ALXN2350 in adult participants with BAG3 associated DCM.

The group in the trial

  • ALXN2350Treatment being tested

    Participants will receive one of three dose levels of ALXN2350 depending on the cohort.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 1/2, Open-Label, Multicenter, Dose Finding and Dose Expansion Study to Investigate the Safety, Tolerability, and Efficacy of ALXN2350 Gene Therapy in Adult Participants With BAG3 Mutation Associated Dilated Cardiomyopathy
Plain-language title
ALXN2350 gene therapy for dilated cardiomyopathy linked to BAG3 gene changesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07218887, who can take part
Record updated
28 August 2026